Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company
advancing personalized medicine in cardiology, oncology, and inherited
diseases through advanced diagnostic tests and clinical and research
services, today announced that Chief Executive Officer Paul Kinnon will
give a corporate presentation at the 8 th Annual OneMedForum
Conference being held at the Marriott Marquis Hotel in San Francisco,
Accelerates RG-101 for HCV with Dual-Track Clinical Development Strategy; Top-Line, Single Dose, 4 mg/kg Results as Well as 2mg/kg Extended Follow Up Results from Ongoing Study to be Reported in Early February 2015
Aims to Advance microRNA Therapeutics Portfolio and Regulus microMarkersSM Division LA JOLLA, Calif.
Proprietary topical compounded formulations offer the promise of significantly reducing the number of patient eye drop administrations as well as the high cost of eye drops typically required for traditional treatment
Results of an investigator-initiated evaluation of the company's Pred-Moxi and Tri-Moxi topical eye drops for patients following LASIK surgery expected to be announced by end of January 2015 SAN DIEGO , Jan.
Fourth quarter revenue of $33.6 million, an increase of 15.5% from the year-ago quarter on a preliminary, unaudited basis Fourth quarter revenue exceeds top-end of company's guidance range
Sign-up for INVENSENSE ALERT: National Securities Law Firm Announces the Filing of a Lawsuit to Recover Losses for Shareholders. Encourages Investors With Losses to Contact Law Firm for More Information investment picks
By Angela Chen
Global Payments Inc. said its revenue rose 10% in the November-ended quarter as the electronics-payments company continues to look at possible acquisitions and expand into the Asian market.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.